Latest Technology Platforms News

Plenti Group has reported a third consecutive record quarter with $437 million in loan originations, driven by strong automotive and NAB partnership growth. The fintech lender also secured a key government contract and continues to deliver low credit losses.

BetMakers Technology Group delivered a standout Q4 FY25 with record adjusted EBITDA and improved margins, while announcing a strategic acquisition to deepen its US market presence.

Visionflex Group delivered a standout Q4 FY25, posting $2.1 million in cash receipts and securing transformative contracts that underpin its expanding virtual healthcare footprint.

betr Entertainment Limited has launched an all-scrip takeover bid for PointsBet Holdings Limited, offering 3.81 betr shares for every PointsBet share, valuing PointsBet at $1.22 per share and promising significant cost synergies.

betr Entertainment has achieved positive EBITDA for FY25, exceeding broker forecasts by 15%, driven by successful mergers and technology integration.

Netwealth Group Limited has reported a record $15.8 billion in Funds Under Administration net flows for FY25, marking a 40% increase over the previous year and pushing total FUA to $112.8 billion. The company’s strong platform growth and strategic board appointment signal continued momentum.

Vitasora Health has completed the first tranche of its $11 million capital raise, positioning the company to fund growth initiatives and reach cash flow breakeven in the second half of fiscal 2026.

DroneShield Limited has landed a significant $11.7 million follow-on research contract from a Five Eyes Department of Defence customer, marking its fourth award from this strategic alliance.

Netlinkz Limited reports $4.8 million in quarterly customer receipts, exits Starlink operations, and pivots to a joint venture in the Philippines to drive growth across ASEAN markets.

Vitasora Health Limited has raised $11 million in a well-supported placement, positioning the company to achieve cash flow breakeven in the second half of FY2026. The capital injection underscores strong investor confidence following key contract expansions and operational milestones.

Mesoblast has secured FDA agreement on key requirements for its Biologics License Application for Revascor, targeting ischemic heart failure patients with reduced ejection fraction. The company aims for accelerated approval by year-end 2025.

Vinyl Group unveils its FY26 vision, shifting focus from growth to scalable profitability by leveraging AI-driven technology to connect millions of music creators, fans, and brands.